A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19
Authors: O’Donnell Max R. , Grinsztejn Beatriz , Cummings Matthew J. , Justman Jessica , Lamb Matthew R. , Eckhardt Christina M. , Philip Neena M. , Cheung Ying Kuen , Gupta Vinay , João Esau , Pilotto Jose Henrique , Diniz Maria Pia , Cardoso Sandra Wagner , Abrams Darryl , Rajagopalan Kartik , Borden Sarah , Wolf Allison , Sidi Leon Claude , Vizzoni Alexandre , Veloso Valdilea G. , Bitan Zachary C. , Scotto Dawn E. , Meyer Benjamin J. , Jacobson Samuel D. , Kantor Alex , Mishra Nischay , Chauhan Lokendra V. , Stone Elizabeth , Dei Zotti Flavia , La Carpia Francesca , Hudson Krystalyn E. , Ferrera Stephen A. , Schwartz Joseph , Stotler Brie , Lin Wen-Hsuan , Wontakal Sandeep , Shaz Beth , Briese Thomas , Hod Eldad A. , Spitalnik Steven L. , Eisenberger Andrew , Lipkin W. Ian 
Published: March 2021

AbstractBackgroundAlthough convalescent plasma has been widely used to treat severe coronavirus disease 2019 (COVID-19), data from randomized controlled trials that support its efficacy are limited.ObjectiveTo evaluate the clinical efficacy and safety of convalescent plasma among adults hospitalized with severe and critical COVID-19.DesignRandomized, double-blind, controlled, multicenter, phase 2 trial conducted from April 21st to November 27th, 2020.SettingFive hospitals in New York City (NY, USA) and Rio de Janeiro (Brazil).ParticipantsHospitalized patients aged ≥18 years with laboratory-confirmed COVID-19, infiltrates on chest imaging and oxygen saturation ≤ 94% on room air or requirement for supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.InterventionParticipants were randomized 2:1 to a single transfusion of either 1 unit of convalescent or normal control plasma.MeasurementsThe primary outcome was clinical status at 28 days, measured using an ordinal scale and analyzed using a proportional odds model in the intention-to-treat population.ResultsOf 223 participants enrolled, 150 were randomized to receive convalescent plasma and 73 to normal control plasma. At 28 days, no significant improvement in clinical status was observed in participants randomized to convalescent plasma (with an odds ratio (OR) of a 1-point improvement in the scale: 1.50, 95% confidence interval (CI) 0.83-2.68, p=0.180).However, 28-day mortality was significantly lower in participants randomized to convalescent plasma versus control plasma (19/150 [12.6%] versus 18/73 [24.6%], OR 0.44, 95% CI 0.22-0.91, p=0.034). The median titer of anti-SARS-CoV-2 neutralizing antibody in infused convalescent plasma units was 1:160 (IQR 1:80-1:320). In a subset of nasopharyngeal swab samples (n=40) from Brazil that underwent genomic sequencing, no evidence of neutralization-escape mutants was detected. Serious adverse events occurred in 39/147 (27%) participants who received convalescent plasma and 26/72 (36%) participants who received control plasma.LimitationsSome participants did not receive high-titer convalescent plasma.ConclusionIn adults hospitalized with severe COVID-19, use of convalescent plasma was not associated with significant improvement in 28 days clinical status. The significant reduction in mortality associated with convalescent plasma, however, may warrant further evaluation.RegistrationClinicalTrials.gov, NCT04359810FundingAmazon FoundationClinical Trial RegistrationClinicalTrials.gov Identifier: NCT04359810